Hayden is an assistant editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2021, where she produces written and video content covering multiple disease states.
She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on LinkedIn.
T1D Community Helped Create T1D Index, Says JDRF's Tom Robinson
December 17th 2022Tom Robinson, vice president of global access at JDRF, talks about how the community and people living with type 1 diabetes (T1D) have contributed to the T1D Index, from development to publication and going forward.
Read More
Dr Patrick Reville Covers Study Results on Venetoclax Combined With CLIA
December 16th 2022Patrick Reville, MD, MPH, instructor, Department of Leukemia, MD Anderson Cancer Center, discusses findings on an updated treatment regimen for newly-diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Read More
How Ochsner, Xavier Are Working Together to Make Louisiana a Healthy State
December 15th 2022Leaders from Ochsner, Xavier, and their partners gathered on September 13, 2022, in New Orleans to offer an overview of the Healthy State initiative during a session of the Institute for Value-Based Medicine®.
Read More
Conversations Around HIV PrEP With Adolescents Vary Between Urban, Rural Family Physicians
December 15th 2022This new study shows that family medicine physicians in rural areas tend to be less comfortable in HIV pre-exposure prophylaxis (PrEP)-related clinical activities and conversations with adolescents than those in urban areas.
Read More
Dr Mary Cushman: Disparities in Pulmonary Embolism Exist; We Need to Ask Why
December 14th 2022Health care providers must acknowledge unconscious bias and watch for it to make sure treatments are given equitably, said Mary Cushman, MD, professor of medicine at the University of Vermont, director of the thrombosis and hemostasis program at the University of Vermont Medical Center.
Read More
TRANSFORM Data Support Liso-cel as Second-line Treatment for LBCL, Says Dr Jeremy Abramson
December 13th 2022The longer follow-up in the primary analysis of TRANSFORM provides confidence in the durability of patient responses to lisocabtagene maraleucel (liso-cel), said Jeremy Abramson, MD, director of the lymphoma program, Massachusetts General Hospital Cancer Center.
Read More
Dr Ajai Chari Talks Phase 1 Results of Bispecific Antibody Talquetamab for Multiple Myeloma
December 13th 2022Ajai Chari, MD, professor of medicine, director of clinical research, Icahn School of Medicine at Mount Sinai, explains the mechanism of action of talquetamab and what method of delivery patients may prefer.
Read More
Dr Elias Jabbour: Third-line Ponatinib “Optimal” for Patients With CML-CP Without T3151 Mutation
December 12th 2022Third-line ponatinib is the optimal treatment option for patients with chronic myeloid leukemia in chronic phase (CML-CP) without T3151 mutation, said Elias Jabbour, MD, professor of medicine, Department of Leukemia, MD Anderson Cancer Center.
Read More
Breakthrough COVID-19 Infection in 10% of Patients With Blood Cancer, LLS Data Show
December 12th 2022About 10% of patients with blood cancer, especially those with B-cell lymphomas, who did not make anti-spike antibodies after vaccination experienced breakthrough COVID-19 infection, said Lee Greenberger, PhD, chief scientific officer, Leukemia and Lymphoma Society.
Read More
Dr Steven Pipe: What to Watch for in the Hemophilia Therapy Pipeline
December 10th 2022The field of hemophilia therapy is advancing, with hemostatic rebalancing agents and gene therapy expected over the next year, said Steven W. Pipe, MD, a professor of pediatrics and pathology at the University of Michigan, Ann Arbor and medical director of the Pediatric Hemophilia and Coagulation Disorders Program and medical director of the Special Coagulation Laboratory.
Read More
Dr Emma Searle Previews MajesTEC-2 Data to Be Presented at ASH 2022
December 7th 2022Emma Searle, PhD, consultant hematologist, The Christie Hospital NHS Foundation Trust, touches on key points learnt from MajesTEC-2 data and other data to look forward to at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
Read More
Dr Neil Iyengar Previews SABCS Presentation on Metabolic Dysregulation in Breast Cancer
December 5th 2022Neil Iyengar, MD, from Memorial Sloan Kettering Cancer Center, is expecting updates on therapies to fight human epidermal growth factor 2 (HER2)–positive breast cancer and novel antibody drug conjugates at the upcoming San Antonio Breast Cancer Symposium (SABCS).
Read More
Dr Steven Pipe on Current Trends in Hemophilia Incidence
December 2nd 2022About 1 in 5000 males are born with hemophilia, according to Steven W. Pipe, MD, a professor of pediatrics and pathology at the University of Michigan, Ann Arbor and medical director of the Pediatric Hemophilia and Coagulation Disorders Program.
Read More
Dr Kevin Astle: Long-Acting Injectables Are a Game Changer for Adherence
November 26th 2022Now that long-acting injectables are approved, the next big concern is patient access, said Kevin N. Astle, PharmD, BCPS, BCACP, AAHIVP, CDES, assistant professor at the University of South Florida Taneja College of Pharmacy.
Read More
T1D Index Will Be Updated Annually, JDRF’s Tom Robinson Explains
November 24th 2022Updating the Type 1 Diabetes (T1D) Index each year with the latest data and literature and implementing feedback is important for at least the first few years, said Tom Robinson, vice president of global access at JDRF.
Read More
Long-Acting Injectables Promote PrEP Access, Adherence, Says Dr Tam Phan
November 22nd 2022Tam C. Phan, PharmD, AAHIVP, assistant professor of clinical pharmacy, USC School of Pharmacy, talks about how HIV pre-exposure prophylaxis (PrEP) therapies in the pipeline address disparities in patient access and adherence.
Read More
MA Beneficiaries May Be at Disadvantage for Complex Cancer Surgeries
November 21st 2022Patients with Medicare Advantage (MA) were 1.5 times more likely to die within a month of surgical removal of their stomach or liver, and twice as likely to die within a month of oncologic surgery of the pancreas, compared with patients with traditional Medicare.
Read More